S

Summit Therapeutics
D

SMMT

19.450
USD
-0.03
(-0.15%)
مغلق
حجم التداول
55,285
الربح لكل سهم
0
العائد الربحي
0
P/E
-177
حجم السوق
14,293,613,787
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLCM
    -0.01620
    (-4.09%)
    0.36000 USD
    B
    BLUE
    -0.06000
    (-5.26%)
    1.08000 USD
    C
    CRSP
    -2.450
    (-4.28%)
    54.840 USD
    E
    EDIT
    -0.28500
    (-5.26%)
    5.13500 USD
    F
    FGEN
    -0.05200
    (-9.77%)
    0.48000 USD
    K
    KPTI
    -0.06290
    (-6.37%)
    0.92380 USD
    M
    MDGL
    -6.22
    (-2.18%)
    278.97 USD
    Q
    QURE
    -0.14500
    (-1.89%)
    7.51000 USD
    R
    RARE
    -0.870
    (-1.93%)
    44.140 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    المزيد
الأخبار
المقالات

العنوان: Summit Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.